Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
Ying Chi(China Three Gorges University), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Bin Wu(Union Hospital), Tina Wu(Yale University), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Wen Tian(Shanghai Jiao Tong University), Baoli Zhu(Nanjing Medical University), Jingxian Liu(Jiangsu Provincial Center for Disease Control and Prevention), Wenshuai Zhang(Jiangsu Provincial Center for Disease Control and Prevention), Chao Huang(Jiangsu Provincial Center for Disease Control and Prevention), Yiyue Ge(Jiangsu Provincial Center for Disease Control and Prevention), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Yongjun Jiao(Jiangsu Provincial Center for Disease Control and Prevention)
Cited by 391
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China
|Hepatology|2020|448
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|Signal Transduction and Targeted Therapy|2021|204